Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
For four consecutive years! Healthy Yuan has once again been awarded the Shanghai Stock Exchange's
Published Time：
2024-10-12
Recently, the Shanghai Stock Exchange (hereinafter referred to as the SSE) released the "Evaluation Results of Information Disclosure Work of Shanghai Main Board Listed Companies in 2023-2024." HealthGen (600380), with its robust operating performance, standardized corporate operations, high-quality information disclosure, and excellent investor relations management, once again received the highest rating of "A" (Excellent) for the SSE's 2023-2024 information disclosure work. This is the fourth consecutive year the company has received this honor.
Since the SSE revised and released the "Shanghai Stock Exchange Listed Company Self-Disciplinary Supervision Guideline No. 9—Information Disclosure Work Evaluation (Revised August 2023)", the evaluation requirements for information disclosure work have been comprehensively refined, further raising the standards for achieving an A rating.
It is understood that this assessment covered 2,247 Shanghai main board listed companies, with 425 companies receiving an A rating, accounting for 18.91%. Among the A-rated companies, most are leading companies in their respective sub-sectors and maintain a high level of daily information disclosure quality. In 2023, the SSE comprehensively reformed and refined the rating standards and rules, further raising the threshold for an A rating. HealthGen's receipt of the highest "A" rating for information disclosure for four consecutive years reflects the regulatory authorities' and capital market's recognition and affirmation of the company's information disclosure quality, standardized operation level, and investor relations management.
- Accurate and Timely Information Disclosure
The company has always attached great importance to information disclosure. During the evaluation period, it issued a total of 233 announcements, completing all information disclosure documents with high quality. In addition to the mandatory disclosure requirements of industry guidelines, the company also actively discloses its industry position, core competitiveness, operating model, strategic development, and operating plans in its regular and interim reports, combining industry policies, market dynamics, and its own circumstances. It also adds "chart-style financial summaries" and "product images" to its regular reports for a more intuitive presentation of its operating conditions.
- Conducting Diversified Investor Relations Management
The company emphasizes conducting investor relations management through various forms, actively answering investors' questions, helping investors gain a deeper and more comprehensive understanding of the company, and enhancing investors' recognition of the company's value and business philosophy. Investor relations activities are conducted through platforms such as shareholder meetings, investor briefings, institutional conference calls, receiving visits and research, SSE e-interaction, investor relations WeChat official account, investor hotline, and email. In addition, the optimized "Shareholders' Visit" series of activities and promotional videos featuring executives interpreting the company's performance help investors understand the capital market and deepen their understanding of HealthGen.
- Fulfilling Social Responsibilities and Attaching Importance to ESG Development
To promote the company's comprehensive and sustainable development, the company has continuously released seven social responsibility reports since 2018, and its ESG rating has improved year by year. As of the reporting period, its MSCI rating has reached AA, a leading level in the pharmaceutical industry. In the future, HealthGen will continue to practice the principles of sustainable development, based on green production and green operations, and further strengthen its work in environmental governance and social governance.
In the future, the company will continue to strictly abide by relevant securities regulatory requirements, adhere to high-quality and high-standard information disclosure, and continuously enhance its ability to serve investors. We strive to become a model in the capital market with outstanding performance, efficient development, sound governance, and honest operation, allowing investors to get close, understand, see clearly, and have confidence, continuously improving the company's development capabilities and overall strength.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.